Skip to main content

Find Clinical Trials

Home
Conditions
Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation

Clinical trial condition

Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation

Explore clinical trials studying Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation trial results

Completed

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

NCT02259114

Conditions: Breast Diseases, Breast Neoplasms, CRPC, +10 more
Locations: Not specified

View Trial Details